rilotumumab + cisplatin + capecitabine

**rilotumumab + cisplatin + capecitabine** is a combination regimen investigated primarily for the treatment of advanced, MET-positive gastric or gastro-oesophageal junction adenocarcinoma. **Rilotumumab** is a fully human monoclonal antibody that binds to hepatocyte growth factor (HGF), preventing its interaction with the MET receptor, thus inhibiting downstream signaling involved in cell proliferation, motility, survival, and angiogenesis. **Cisplatin** is a platinum-based chemotherapeutic that induces DNA crosslinking and apoptosis. **Capecitabine** is a prodrug converted to 5-fluorouracil, inhibiting DNA synthesis. This combination was tested in multicenter phase 2/3 clinical trials, sometimes alongside epirubicin as part of triplet therapy for gastric cancers. Rilotumumab was developed by Amgen, but clinical development for gastric cancer was terminated after the RILOMET-1 phase 3 trial showed lack of efficacy and increased mortality in the experimental arm. The regimen is purely investigational and is not approved for any indication[1][2][3][4][5].